Swipe for more

• April 09, 2024

  bioMérieux presents its new 5-year strategic plan and its targets for profitable growth

  bioMérieux, a world leader in the field in vitro diagnostics, is hosting today a Capital Markets Day in Paris. On this occasion, Pierre Boulud, Chief Executive Officer, together with members of the Executive Committee will present bioMérieux’s strategic plan, GO•28, the new chapter for the Company’s growth and development.

  Read more
  

• April 05, 2024

  bioMérieux and Mérieux NutriSciences partner with key food industry players to launch a new collaborative data-driven model

  bioMérieux and Mérieux NutriSciences jointly announce the launch of a new data-driven Trusted Third Party initiative, built with a group of global food industry partners to foster safe industry collaboration as well as better anticipate and prevent food safety risks.

  Read more
  

• March 27, 2024

  Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® R/ST Panel

  bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver approval for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel.

  Read more